Amphastar Pharmaceuticals clinical trials we track

Check company identity source

Phase 2 / 3 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 60 participants (planned). After: 62 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jun 2026. After: 22 Jun 2026.

Recruitment status changed

Before: Recruiting. After: Completed.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Maximum Serum Insulin Aspart Concentration, CIAmax Measure: Area Under the Curve (AUC) of Insulin Aspart Serum Concentration from time 0 to 12 hours post-dose, AUCIA(0-12h) Measure: Maximum Serum Human Insulin Concentration, CHImax Measure: Area Under the Curve (AUC) of Human Insulin Serum Concentration from time 0 to 12 hours post-dose, AUCHI(0-12h) Measure: Maximum Glucose Infusion Rate, Gmax Measure: Area Under the Curve (AUC) for Glucose Infusion Rate from time 0 to 12 hours post-dose, AUCG(0-12h). After: Measure: Maximum Serum Insulin Aspart Concentration, CIAmax Measure: Area Under the Curve (AUC) of Insulin Aspart Serum Concentration From Time 0 to 12 Hours Post-dose, AUCIA(0-12h) Measure: Maximum Glucose Infusion Rate, Gmax Measure: Area Under the Curve (AUC) for Glucose Infusion Rate From Time 0 to 12 Hours Post-dose, AUCG(0-12h).

Check registry source